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Expression of Basal-Cell Adhesion Molecule (B-CAM) in
Human Epidermis
To the Editor:
I read with interest the recent article by SchoÈn et al on the
expression of basal-cell adhesion molecule (B-CAM) in human skin
(SchoÈn et al, 2000) documenting association of B-CAM expression
with activated states of keratinocytes. The authors provide
convincing evidence that, besides its known function as a laminin
receptor, B-CAM may be involved in cell±cell interaction or
migration.
In this context I would like to bring to your attention data
regarding B-CAM expression in human skin that might not have
been accessible to the authors at the time their manuscript was
submitted. We have been analyzing B-CAM expression in normal
and diseased human skin utilizing the monoclonal antibody G253
that has also been employed in the paper by SchoÈn et al. Contrary
to their observation, but in line with previous ®ndings (Garin-
Chesa et al, 1994), the majority of specimen from normal human
epidermis exhibited B-CAM positive suprabasal keratinocytes. In
contrast, B-CAM expression in fetal epidermis was restricted to
basal keratinocytes. The outer root sheath of hair follicles in both
fetal as well as adult human skin regularly exhibited a B-CAM
positive phenotype. The level of B-CAM expression was higher in
psoriasis and contact dermatitis. We interpret our observations as
evidence for B-CAM being a keratinocyte differentiation marker
(Bernemann et al, 2000). This notion is supported by the effects of
Ca2+ levels on the B-CAM phenotype of keratinocytes as described
by SchoÈn et al.
Wolf-Henning Boehncke
Department of Dermatology, Frankfurt University
Medical School, Frankfurt, Germany
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Maternal Transmission of the 3 bp Deletion within Exon 7 of
the STS Gene in Steroid Sulfatase De®ciency
To the Editor:
Steroid sulfatase (STS) enzyme (EC 3.1.6.2) is present in the
microsomal fraction of the cell and is capable of hydrolyzing
sulfated sterols (Hobkirk, 1985; Dibbelt and Kuss, 1991). STS
de®ciency is the biochemical defect in X-linked ichthyosis (XLI), a
disease that clinically presents dark, adhesive, and regular scales of
skin (Shapiro and Weiss, 1978). STS assay or FISH analyzes allow
an XLI diagnosis and identify XLI-carriers (Baden et al, 1980;
Epstein and Leventhal, 1981; Okano et al, 1985; Hermann et al,
1987; Matsumoto et al, 1990; Aviram-Goldring et al, 2000). STS
enzyme is encoded by the STS gene on the short arm of the
X-chromosome (Muller et al, 1981). Most STS enzyme de®cient
patients present large deletions of the entire STS gene and ¯anking
sequences (Bonifas et al, 1987; Shapiro et al, 1989; Cuevas-
Covarrubias et al, 1997; Aviram-Goldring et al, 2000). Only a few
point mutations or partial deletions have been identi®ed (Bonifas
et al, 1987; Ballabio et al, 1989; Shapiro et al, 1989; Basler et al,
1992; Nomura et al, 1995; Alperin and Shapiro, 1997; Morita et al,
1997; Aviram-Goldring et al, 2000; Oyama et al, 2000; Sugawara et
al, 2000; Valdes et al, 2000). In this study, we describe an XLI
patient with the ®rst 3 bp intragenic deletion of the STS gene
causing XLI and demonstrate the maternal transmission of this
molecular defect.
MATERIALS AND METHODS
Patient The patient was referred as having ichthyosis to the General
Hospital of Mexico. He was the only child of the family. The patient
and his mother were informed about the characteristics of the study and
they agreed to participate. Protocol was evaluated and approved by the
Ethics Committee. The patient showed a moderate degree of
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